Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples

Ilié, Marius; Hofman, Véronique; Bontoux, Christophe; Goffinet, Samantha; Benzaquen, Jonathan; Heeke, Simon; Boutros, Jacques; Lassalle, Sandra; Long‐Mira, Elodie; Zahaf, Katia; Lalvee, Salomé; Lespinet‐Fabre, Virginie; Bordone, Olivier; Tanga, Virginie; Gómez-Caro, Abel; Cohen, Charlotte; Berthet, Jean‐Philippe; Marquette, Charles‐Hugo; Hofman, Paul

doi:10.1016/j.lungcan.2023.107230

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In thoracic oncology, the development of antibody drug conjugates (ADCs) has led to new treatment options for NSCLC and small-cell lung cancer [ 25 , 29 ], with associated predictive biomarkers [ 25 – 29 ]. These biomarkers (such as c-MET, TROP2, CEACAM5, DLL3, HER3, HER2, and B7-H3) can be identified using IHC or molecular tests [ 27 , 30 , 31 ].…”

Section: Molecular Biomarkers For Lung Cancersmentioning

confidence: 99%

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Hofman,

Berezowska,

Kazdal

et al. 2023

Virchows Arch

View full text Add to dashboard Cite

The continuing evolution of treatment options in thoracic oncology requires the pathologist to regularly update diagnostic algorithms for management of tumor samples. It is essential to decide on the best way to use tissue biopsies, cytological samples, as well as liquid biopsies to identify the different mandatory predictive biomarkers of lung cancers in a short turnaround time. However, biological resources and laboratory member workforce are limited and may be not sufficient for the increased complexity of molecular pathological analyses and for complementary translational research development. In this context, the surgical pathologist is the only one who makes the decisions whether or not to send specimens to immunohistochemical and molecular pathology platforms. Moreover, the pathologist can rapidly contact the oncologist to obtain a new tissue biopsy and/or a liquid biopsy if he/she considers that the biological material is not sufficient in quantity or quality for assessment of predictive biomarkers. Inadequate control of algorithms and sampling workflow may lead to false negative, inconclusive, and incomplete findings, resulting in inappropriate choice of therapeutic strategy and potentially poor outcome for patients. International guidelines for lung cancer treatment are based on the results of the expression of different proteins and on genomic alterations. These guidelines have been established taking into consideration the best practices to be set up in clinical and molecular pathology laboratories. This review addresses the current predictive biomarkers and algorithms for use in thoracic oncology molecular pathology as well as the central role of the pathologist, notably in the molecular tumor board and her/his participation in the treatment decision-making. The perspectives in this setting will be discussed.

show abstract

Section: Molecular Biomarkers For Lung Cancersmentioning

confidence: 99%

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Hofman,

Berezowska,

Kazdal

et al. 2023

Virchows Arch

View full text Add to dashboard Cite

show abstract

L’immunohistochimie c-Met en oncologie thoracique, un nouvel enjeu pour le pathologiste

Hofman,

Bontoux,

Goffinet

et al. 2023

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

c-Met immunohistochemistry as reflex test at diagnosis for non-small cell lung cancer: a real-world experience from a monocentric case series

Bontoux,

Hofman,

Abboute

et al. 2023

J Clin Pathol

View full text Add to dashboard Cite

AimsRecent clinical trials have shown promising results with drugs targeting the hepatocyte growth factor receptor (c-Met) for advanced non-small cell lung cancers overexpressing c-Met. We assessed reflex testing of c-Met immunohistochemistry (IHC) at diagnosis for NSCLC in the real-world.MethodsWe retrospectively collected clinical, pathological and molecular data of cases diagnosed with NSCLC in our institution from January 2021 to June 2023. We performed c-Met IHC (SP44 clone) and scored the expression using a H-score and a three-tier classification.Results391 cases with interpretable c-Met IHC staining were included. The median age at diagnosis was 70 years (range 25–89 years) including 234 males (male/female ratio 1:5). 58% of the samples came from surgical resections, 35% from biopsies and 8% from cytological procedures. 52% of cases were classified as c-Met-positive (H-score≥150) and 19% were classified as c-Methigh(≥50%, 3+). 43% of the c-Metnegpresented with lymph node and/or visceral metastases at diagnosis vs 55% for c-Methigh(p=0.042). 23% of the adenocarcinomas showed c-Methighexpression vs 3% for squamous cell carcinomas (p=0.004). 27% of the c-Metnegcases had a high PD-L1 expression vs 58% of c-Methighcases (p<0.001).METex14 skipping was present in 8% of the c-Methighcases.ConclusionsSystematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features.

show abstract

Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples

Cited by 3 publications

References 41 publications

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

L’immunohistochimie c-Met en oncologie thoracique, un nouvel enjeu pour le pathologiste

c-Met immunohistochemistry as reflex test at diagnosis for non-small cell lung cancer: a real-world experience from a monocentric case series

Contact Info

Product

Resources

About